Fig. 3: Effect of TRPV4 genetic ablation on PAR1-induced vascular hyperpermeability.

Evans Blue retention measured in regions involved in the airways (a–c) or upper GI tract and jejunum (d–f). Wildtype or TRPV4^−/− mice were treated with vehicle alone or with the PAR1 agonist peptide TFLLR (3 µmol/kg). Each data point represents a measurement from an individual animal, column graphs represent mean ± s.e.m., n = 5–6. *, ^#p < 0.05; **, ^##p < 0.01; two-way ANOVA with Sidak’s multiple comparisons test; relative to Vehicle only control (*) or Vehicle + TFLLR treatment (#).